After the voluntary withdrawal of Vioxx from the market in September 2004 following reports of increased cardiovascular events associated with the drug, there was a call from some quarters for a similar action for all selective COX-2 inhibitors (coxibs). This article reviews the current clinical knowledge regarding the coxibs and their cardiovascular effects. Recommendations for prescribing anti-inflammatory drugs in common clinical situations are provided.